Levodopa-induced dyskinesias and substantia nigra dopamine D3 receptor availability in Parkinson’s disease
Objective: To investigate with PET and the radioligand [11C]PHNO whether levodopa-induced dyskinesias in Parkinson disease (PD) are associated with dopamine-D3 receptor (D3R) overexpression in substantia nigra…Correlation between location of active contacts and weight gain after subthalamic nucleus deep brain stimulation in Parkinson’s disease
Objective: Objective: The aim of this study was to evaluate the correlation between the location of active contacts and weight gain after subthalamic nucleus deep…Mechanisms of chronic neuroleptic-induced parkinsonism examined with positron emission tomography
Objective: To investigate the cause of chronic neuroleptic drug-induced parkinsonism (NIP) through examination of the profile of striatal monoaminergic nerve terminal density using positron emission…Dopaminergic denervation in de-novo Parkinson’s disease. Does functional somatotopy plays a role?
Objective: To clarify how dopaminergic denervation occurs along the dorsoventral axis of the posterior putamen in the earliest stages of PD. Background: Dopamine loss in…Topographical subtypes of multiple system atrophy: MRI and PET studies
Objective: To investigate the MSA subtypes based on the topography of MSA lesions, employing MRI, PET with [18F]FP-CIT and [18F]FDG PET. Background: Based on the…A longitudinal PET study to assess the state of microglia activation in a Phase 2 study of Laquinimod as a treatment for Huntington’s disease (LEGATO-HD)
Objective: To assess in vivo in Huntington’s disease (HD) changes in microglia activation state, due to treatment with laquinimod, as reflected by changes in 11C-PBR28…Automated pattern based classification in neuropathology proven parkinsonism
Objective: In patients with parkinsonism and uncertain differential diagnosis, an automated image-based algorithm can help to distinguish idiopathic Parkinson’s disease (IPD) from atypical parkinsonian syndromes…Brain 5-HT1 receptor binding in multiple system atrophy: A [18F]-MPPF PET study
Objective: The primary objective was to compare brain 5-HT1a receptor binding between patients with multiple system atrophy (MSA) and healthy controls (HC). The secondary objectives…Imaging Parkinson’s disease pathology: A comparison between neuromelanin-sensitive MRI, susceptibility weighted imaging and [11C]PE2I DAT PET
Objective: We compared 2 novel MRI techniques: neuromelanin-sensitive MRI (NM-MRI) and susceptibility weighted imaging (SWI) with [11C]PE2I PET in order to establish their validity as biomarkers…Characteristics of the clinical and cerebral metabolism in Parkinson’s disease with atrophy in nucleus basalis of Meynert
Objective: We investigated characteristics of clinical and cerebral glucose metabolic abnormalities in Parkinson’s disease (PD) with atrophy in the nucleus basalis of Meynert (NBM). Background:…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 35
- Next Page »